Monopar Therapeutics (NASDAQ:MNPR) Earns Buy Rating from Analysts at Chardan Capital

Research analysts at Chardan Capital began coverage on shares of Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) in a research note issued to investors on Monday,Benzinga reports. The firm set a "buy" rating and a $60.00 price target on the stock. Chardan Capital's target price indicates a potential upside of 82.59% from the stock's current price.

A number of other research analysts have also commented on the company. Wall Street Zen raised Monopar Therapeutics from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. HC Wainwright reissued a "buy" rating and issued a $40.00 target price on shares of Monopar Therapeutics in a research report on Tuesday, April 1st. Jones Trading reaffirmed a "hold" rating on shares of Monopar Therapeutics in a research report on Wednesday, April 2nd. Finally, Piper Sandler reiterated an "overweight" rating and issued a $76.00 price objective on shares of Monopar Therapeutics in a research note on Wednesday, March 19th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $56.50.

Monopar Therapeutics Price Performance

NASDAQ:MNPR opened at $32.86 on Monday. The company has a market cap of $201.10 million, a P/E ratio of -9.44 and a beta of 1.00. The firm's fifty day moving average price is $37.30 and its two-hundred day moving average price is $34.55. Monopar Therapeutics has a one year low of $1.72 and a one year high of $54.30.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.65) by $0.27. As a group, equities research analysts expect that Monopar Therapeutics will post -1.65 earnings per share for the current year.

Insider Transactions at Monopar Therapeutics

In related news, major shareholder Tactic Pharma Llc sold 33,334 shares of the stock in a transaction that occurred on Wednesday, April 2nd. The shares were sold at an average price of $35.00, for a total transaction of $1,166,690.00. Following the sale, the insider now owns 822,255 shares in the company, valued at approximately $28,778,925. This trade represents a 3.90% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 20.50% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in MNPR. Janus Henderson Group PLC acquired a new stake in shares of Monopar Therapeutics in the 4th quarter valued at $23,435,000. Adage Capital Partners GP L.L.C. bought a new position in Monopar Therapeutics in the fourth quarter valued at about $13,182,000. RA Capital Management L.P. acquired a new position in Monopar Therapeutics during the fourth quarter worth about $11,247,000. Point72 Asset Management L.P. bought a new position in shares of Monopar Therapeutics in the fourth quarter worth about $3,694,000. Finally, ADAR1 Capital Management LLC acquired a new stake in shares of Monopar Therapeutics in the 4th quarter valued at approximately $2,861,000. 1.83% of the stock is currently owned by institutional investors and hedge funds.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.